Trial Profile
A Phase IB Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Hematologic Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Birabresib (Primary)
- Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 29 Sep 2021 Status changed from active, no longer recruiting to discontinued due to limited efficacy and not due to safety reasons.
- 12 Jul 2021 Planned End Date changed from 30 Jun 2021 to 31 Dec 2021.
- 06 Jan 2021 Planned End Date changed from 31 Dec 2020 to 30 Jun 2021.